Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19303144 | 0.94 | ALDH1A1 (0.47) | KCNH2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL16224793 | 0.82 | KDM4E (0.53) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL3971206 | 0.80 | KDM4E (0.50) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL9338962 | 0.74 | PDE4A (0.46) | ALDH1A1KDM4EL3MBTL1HPGDGAA | |
| SCHEMBL19772111 | 0.74 | KDM4E (0.48) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL7219744 | 0.73 | KCNH2 (0.42) | KCNH2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL23462738 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KDM4EL3MBTL1MAPTTHRB | |
| SCHEMBL3967032 | 0.71 | KDM4E (0.54) | ALDH1A1MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL18176098 | 0.70 | KCNH2 (0.42) | KCNH2L3MBTL1 | |
| SCHEMBL20289391 | 0.70 | AR (0.54) | ALDH1A1KDM4EARTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | KCNH2 2308/4885ALDH1A1 1457/4885MEN1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.